Rhodium Ruthenium Metalloinsertor Complexes Targeting MMR-Deficient Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current metalloinsertors are unable to induce cell death in mismatch repair (MMR)-deficient cells, despite their ability to target DNA mismatches, highlighting a need for a therapeutic agent that can selectively target and inhibit the proliferation of MMR-deficient cells.
Innovation Solution
Development of rhodium and ruthenium metalloinsertor complexes, specifically represented by Formula I, which include ligands like benzo[a]phenazine-5,6-diimine and chrysene-5,6-diimine, designed to selectively target and induce cytotoxicity in MMR-deficient cells by binding to mismatched DNA sites, thereby inhibiting cellular proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing metalloinsertors are used to target DNA mismatches, then mismatch detection capability is improved, but cell death induction capability deteriorates
Solution Approach 1:
The patent modifies the chemical parameters of the metalloinsertor by changing the ligand structure from traditional bipyridine-based ligands to phenazine or diiminochrysene ligands. This parameter change transforms the molecule from a mismatch-detecting agent to a cytotoxic agent that can induce cell death in MMR-deficient cells while maintaining mismatch targeting capability
Solution Approach 2:
The invention creates a composite structure by combining the metalloinsertor core with specific organic ligands (phenazine or diiminochrysene) that possess both mismatch-binding affinity and cytotoxic properties. This composite approach integrates detection and therapeutic functions into a single molecule
2Manufacturing precision
If metalloinsertors bind to mismatched DNA sites, then targeting specificity is improved, but therapeutic efficacy deteriorates
Solution Approach 1:
The metalloinsertor is designed to perform multiple functions: it maintains its ability to specifically bind to mismatched DNA sites while simultaneously acquiring the ability to induce cytotoxicity. This multi-functionality resolves the contradiction between targeting specificity and therapeutic efficacy by making the same molecule both a precise targeter and an effective therapeutic agent
3Productivity
If MMR-deficient cells are enriched due to resistance to common agents, then cell proliferation is improved, but treatment difficulty deteriorates
Solution Approach 1:
The patent exploits the characteristic of MMR-deficient cells (their resistance to common agents and enrichment in cancer populations) by designing a metalloinsertor that specifically targets and kills these cells. The deficiency that causes treatment resistance is converted into a vulnerability that the metalloinsertor exploits through mismatch-specific binding and cytotoxicity induction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The metalloinsertor complexes demonstrate selective cytotoxicity and inhibition of cell proliferation in MMR-deficient cells, showcasing enhanced cellular uptake and binding affinity, leading to effective targeting and treatment of cells with impaired mismatch repair mechanisms.
Implementation Method 1
Mm+(L1)(L2)(L3)(L4)(L5) where M is rhodium or ruthenium, and L1 is benzo[a]phenazine-5,6-diimine (phzi) or chrysene-5,6-diimine (chrysi)
Data Source
AI summary
A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes.